Back to medical news
MedPage Today
U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis Drug
August 24, 2026
Original source summary
(MedPage Today) -- A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull...
Verbatim from MedPage Today's own feed — "U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis Drug"
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
More medical news